Reboxetine: tolerability and safety profile
in patients with major depression.

Tanum L

Department of Psychosomatic
and Behavioural Medicine,
Rikshospitalet, Oslo, Norway.
Acta Psychiatr Scand Suppl 2000; 402:37-40

ABSTRACT

Since reboxetine acts selectively on the reuptake of noradrenaline, it has a different side-effects profile than drugs acting predominantly on the serotonin reuptake mechanism.  Data from patients treated with reboxetine (n = 1503) or placebo/comparator drugs (n = 1027) show that reboxetine has no significant cardiovascular effects, a low potential for drug interactions, causes no significant impairment of cognitive or motor function and no increase in suicidal ideation. In contrast to certain serotonergic drugs, there is no evidence of any withdrawal syndrome upon abrupt discontinuation or tapering of reboxetine treatment. Sexual dysfunction appears in only a small fraction of the patients and mainly with doses higher than 8 mg daily. The rate of discontinuation due to adverse effects with reboxetine was not significantly different from that observed with placebo in short-term studies. The level of efficacy and apparently favourable tolerability profile makes reboxetine an important alternative in the medical treatment of depressive illness.

Back                          to order

   Reboxetine  research / abstracts

 1.   Reboxetine  role in antidepressant therapy
 2.   Reboxetine  efficacy and tolerability
 3.   Reboxetine  clinical pharmacologic profile
 4.   Reboxetine  Inhibiting noradrenaline and serotonin reuptake 
 5.   Reboxetine  and depression in the elderly
 6.   Reboxetine  with severe major depressive disorder
 7.   Reboxetine  clinical efficacy in major depression
 8.   Reboxetine  tolerability and safety for major depression
 9.   Reboxetine  comparison with fluoxetine
10.  Reboxetine  versus fluoxetine, impact on social functioning
11.  Reboxetine  versus fluoxetine, differential effects
12.  Reboxetine  prevents relapse in  major depression
13.  Reboxetine  efficacy compared with imipramine
14.  Noradrenaline reuptake inhibition
15.  Antidepressants  noradrenergic versus serotonergic
16.  Reboxetine  in the treatment of bulimia
17.  Reboxetine  hemodynamic effects in healthy males
18.  Reboxetine  effects of antidepressant therapy
19.  Reboxetine  place in antidepressant therapy
20.  Reboxetine  stimulant effects in patients with narcolepsy
21.  Reboxetine  selective noradrenaline reuptake inhibitor (NARI)